Recent Development in the Field of Dual COX / 5-LOX Inhibitors

Author(s): Fabien Julemont, Jean-Michel Dogne, Bernard Pirotte, Xavier de Leval.

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 4 , Issue 6 , 2004

Become EABM
Become Reviewer

Abstract:

Cyclooxygenases and lipoxygenase are key enzymes in the arachidonic acid metabolism. Dual inhibitors are drugs able to block both the COX and the 5-LOX metabolic pathways. Compared to COX or LOX pathways single inhibitors, dual inhibitors present at least two major advantages. First, dual inhibitors, by acting on the two major arachidonic acid metabolic pathways, possess a wide range of anti-inflammatory activities. Secondly, dual inhibitors appear to be almost exempt from gastric toxicity, which is the most troublesome side effect of non-selective COX inhibitors.

Keywords: cancer, cyclooxygenases, dual inhibitors, inflammation, leukotrienes

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 4
ISSUE: 6
Year: 2004
Page: [633 - 638]
Pages: 6
DOI: 10.2174/1389557043403747
Price: $58

Article Metrics

PDF: 11